Related Experiment Videos
A pharmacophore for high affinity PAF antagonists. I. Electronic model using molecular electrostatic potential
H Le Solleu1, M Laguerre, M Saux
1G.E.R.S.A.A.C., Laboratoire de Chimie Analytique, UFR des Sciences Pharmaceutiques, Université de Bordeaux II, France.
Journal of Lipid Mediators and Cell Signalling
|May 1, 1996
Summary
This study reveals that potent platelet-activating factor (PAF) antagonists share a common electronic pharmacophore. This electronegative system, characterized by specific distances between zones A, B1, and B2, is crucial for high PAF antagonist affinity.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Computational Chemistry
Background:
- Platelet-activating factor (PAF) is a key phospholipid autacoid in numerous physiological and pathological processes.
- Development of PAF antagonists is a significant therapeutic strategy.
Purpose of the Study:
- To compare the electronic properties of 48 potent PAF antagonists from six distinct chemical series.
- To identify common structural features contributing to high PAF antagonist affinity.
Main Methods:
- Utilized molecular electrostatic potential (MEP) analysis.
- Investigated 48 'heterocyclic sp2 nitrogen' PAF antagonists across six chemical classes.
- Analyzed geometric parameters of electronegative zones.
Main Results:
- Identified a common electronic pharmacophore comprising three electronegative zones (A, B1, B2) in potent PAF antagonists.
- Established characteristic distances for the A-B1, A-B2, and B1-B2 systems (9.3±1.0 Å, 13.4±0.7 Å, 4.9±0.9 Å, respectively).
- Correlated high antagonist affinity with the A-B(x) electronegative system.
Conclusions:
- The A-B(x) electronegative system is a critical determinant of high affinity for these PAF antagonists.
- Zones B1 and B2 may act as anchors within the PAF receptor binding site.
- Findings provide insights for designing novel, potent PAF antagonists.